For the first time, a team of experts from the Technical University of Munich (TUM), RWTH Aachen University, and the German ...

IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Changes in genes have been linked to the development of different diseases for a while. However, it's not exactly clear what ...

NP-G2-044 (Prilukae), a novel oral fascin inhibitor, has earned orphan drug designation (ODD) from the FDA for the treatment ...

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...

Aston Sci. Inc., a clinical-stage biopharmaceutical company pioneering next-generation therapeutic cancer vaccines, announced ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare ...

Global cancer cases have surged dramatically, doubling since 1990 and reaching 18.5 million new diagnoses in 2023. Deaths ...

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid ...

Cancer natives can expect uplifting energies that support health, relationships, business success, and joyful family moments.

Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that ...